Kansa ya tezi-kibofu ni kansa ya pili ya kawaida kwa wanaume ulimwenguni kote, na inakadiriwa kuwa visa vipya 1.276 milioni viliripotiwa mnamo 2018, ikiwakilisha 7.1% ya visa vyote vya saratani kwa wanaume.
Kiwango cha vifo kwa saratani ya tezi pia ni cha juu, na inakadiriwa kuwa vifo 37,005 ulimwenguni kote mnamo 2018.
Hata hivyo, kiwango cha vifo hutofautiana sana kulingana na mkoa, huku Afrika Magharibi ikiwa na hatari ya tano ya vifo vya saratani ya tezi katika ulimwengu, na Nigeria ikiwa na idadi kubwa zaidi ya watu na uchumi katika mkoa huu.
Huko Nigeria, kansa ya tezi-kibofu ndiyo kansa ya kawaida zaidi na yenye kuua zaidi kwa wanaume, ikikadiriwa kuwa na visa 32.8 na vifo 16.3 kwa kila wanaume 100,000.
Hii ni zaidi ya mara mbili ya kiwango cha vifo katika Amerika Kaskazini.
Uchunguzi wa kuchelewa wa ugonjwa huo, rasilimali ndogo za kuchunguza na kugundua, na kupungua kwa nyaraka na kuripoti visa huchangia kiwango cha juu cha vifo nchini Nigeria.
Huko Marekani, kansa ya tezi-kibofu ndiyo kisababishi cha pili cha kawaida cha vifo vya kansa miongoni mwa wanaume, na takriban wanaume 40,000 hufa kutokana na ugonjwa huo kila mwaka.
Kiwango cha vifo vya kansa ya tezi-kibofu kimekuwa kikipungua polepole tangu mwanzoni mwa miaka ya 1990, lakini bado ni wasiwasi mkubwa wa afya.
Kwa ujumla, kansa ya tezi-kibofu ni ugonjwa wenye kuua, hasa katika mikoa yenye upatikanaji mdogo wa huduma za kitiba na rasilimali za uchunguzi.
Hata hivyo, kugundua na kutibu mapema kunaweza kuboresha matokeo na kupunguza viwango vya vifo.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
Kanusho la dhima: matibabu
Tovuti hii hutolewa kwa madhumuni ya elimu na habari tu na si kutoa ushauri wa matibabu au huduma za kitaaluma.
Habari inayotolewa haipaswi kutumiwa kugundua au kutibu tatizo la afya au ugonjwa, na wale wanaotafuta ushauri wa kibinafsi wa kitiba wanapaswa kushauriana na daktari aliye na leseni.
Tafadhali kumbuka mtandao wa neva ambao hutengeneza majibu ya maswali, ni hasa usio sahihi linapokuja maudhui ya nambari. Kwa mfano, idadi ya watu waliogunduliwa na ugonjwa fulani.
Daima kutafuta ushauri wa daktari wako au mtoa huduma nyingine ya afya waliohitimu kuhusu hali ya matibabu. Kamwe kupuuza ushauri wa matibabu ya kitaaluma au kuchelewesha katika kutafuta yake kwa sababu ya kitu umesoma kwenye tovuti hii. Kama unafikiri unaweza kuwa na dharura ya matibabu, piga simu 911 au kwenda chumba cha dharura karibu mara moja. Hakuna uhusiano daktari-mgonjwa ni kuundwa na tovuti hii au matumizi yake. Wala BioMedLib wala wafanyakazi wake, wala mchangiaji yoyote ya tovuti hii, hufanya uwakilishi wowote, wazi au implicit, kuhusiana na taarifa zinazotolewa hapa au matumizi yake.
Utoaji wa dhima: hakimiliki
The Digital Millennium Copyright Act ya 1998, 17 U.S.C. § 512 (the DMCA) hutoa njia ya kurudi kwa wamiliki wa hakimiliki ambao wanaamini kuwa vifaa vinavyoonekana kwenye Mtandao vinakiuka haki zao chini ya sheria ya hakimiliki ya Merika.
Kama unaamini kwa imani nzuri kwamba maudhui yoyote au nyenzo zilizotolewa kuhusiana na tovuti yetu au huduma inakiuka hakimiliki yako, wewe (au wakala wako) unaweza kutuma sisi taarifa kuomba kwamba maudhui au nyenzo kuondolewa, au upatikanaji wake kuzuiwa.
Taarifa lazima zipelekwe kwa maandishi kwa barua pepe (tazama sehemu ya "Contact" kwa anwani ya barua pepe).
DMCA inahitaji kwamba taarifa yako ya madai ya ukiukaji wa hakimiliki ni pamoja na taarifa zifuatazo: (1) maelezo ya kazi ya hakimiliki ambayo ni madai ya ukiukaji; (2) maelezo ya madai ya ukiukaji maudhui na habari ya kutosha kuruhusu sisi kupata maudhui; (3) mawasiliano ya habari kwa ajili yenu, ikiwa ni pamoja na anwani yako, nambari ya simu na anwani ya barua pepe; (4) taarifa na wewe kuwa na imani nzuri imani kwamba maudhui katika njia alilalamika ya si mamlaka na mmiliki wa hakimiliki, au wakala wake, au na operesheni ya sheria yoyote;
(5) taarifa na wewe, saini chini ya adhabu ya ushahidi wa uongo, kwamba habari katika taarifa ni sahihi na kwamba una mamlaka ya kutekeleza haki za hakimiliki ambayo ni madai ya kukiuka;
na (6) saini ya kimwili au ya elektroniki ya mmiliki wa hakimiliki au mtu aliyeidhinishwa kutenda kwa niaba ya mmiliki wa hakimiliki.
Kushindwa kujumuisha habari zote hapo juu kunaweza kusababisha ucheleweshaji wa usindikaji wa malalamiko yako.
Mawasiliano
Tafadhali tutumie barua pepe na swali lolote / pendekezo.
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Karibu
BioMedLib hutumia kompyuta za kiotomatiki (algorithms ya kujifunza mashine) kuzalisha jozi za maswali na majibu.
Tunaanza na machapisho milioni 35 ya biomedical ya PubMed/Medline. Pia, kurasa za wavuti za RefinedWeb.
